Showing 591-600 of 9351 results for "".
Robert Grant Steps Down at Alphaeon; Skin Cancer Special Edition
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-robert-grant-steps-down-at-alphaeon-skin-cancer-special-edition/18595/Robert Grant is no longer CEO of lifestyle healthcare company Alphaeon. Mr. Grant founded Alphaeon in 2013 as a wholly owned subsidiary of Strathspey Crown LLC, a private equity firm located in Newport Beach, CA, where he serves as Chairman. Also in this issue, a closer look at skin cancer. May is SLaser Options for Scars
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-options-for-scars/18814/Advances in laser technology—particularly fractional lasers—offer an effective option for diminishing the appearance of scars, says Jill Waibel, MD. She offers a review of how she's treating all types of scars and skin types, and discusses how and why keloids have been reclassified as a disease.How Effective is the Liquid Facelift?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-effective-is-the-liquid-facelift/18621/Liquid facelifts offer patients a non-surgical approach to creating the same effect as a surgery. Suneel Chilukuri, MD says by combing fillers, neuromodulators, devices, and at-home care, it's possible to tighten, lift, and generate new collagen. He says this non-invasive combination can achieve aboOnexton Approved for Acne, Bellafill Debuts
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-onexton-approved-for-acne-bellafill-debuts/19019/In this edition of DermWireTV, from the editors of Practical Dermatology® magazine: Onexton is Valeant's fourth new approval in a year. We look at Suneva's renamed filler and the FDA's decision to grant breakthrough status to investigational atopic dermatitis treatment dupilumab. PLUS: This week'sCynosure, Cutera Laser Clearances; Surgeon General Takes on Skin Cancer
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cynosure-cutera-laser-clearances-surgeon-general-takes-on-skin-cancer/19096/In this edition of DermWireTV, from the publishers of Practical Dermatology® and Modern Aesthetics® host Devyn Gehrit offers highlights of the annual summer meeting, explores a new skin cancer initiative by the Surgeon General, and covers FDA clearances for Cynosure and Cutera laser systems.Do This Now: Be a Better Leader
https://practicaldermatology.com/topics/practice-management/do-this-now-be-a-better-leader/19111/Speaking at the Vegas Cosmetic Dermatology meeting, Todd E. Schlesinger, MD shares tips for becoming a better leader in your aesthetics practice--whether you own the practice or not. Understanding personalities and leading outside the practice walls are key.Merz Acquires Ulthera; Ulthera Gets Decolletage Indication, and a New Topical for Onychomycosis
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-merz-acquires-ulthera-ulthera-gets-decolletage-indication-and-a-new-topical-for-onychomycosis/19117/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine, learn the latest on the Merz/Ulthera acquisition, a new topical for toenail fungus, and FDA accepts Kythera's NDA.Sunscreen Labeling
https://practicaldermatology.com/topics/practice-management/sunscreen-labeling-/19370/Neal Bhatia, MD discusses the impact of new sunscreen labeling on patient education, as well as strategies for UV avoidance, and trends in therapeutic development.BodyJet Irrigation Liposuction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bodyjet_meyer-irrigation/19519/Demonstration of proper technique for water-assisted liposuction, including placement of cannula and fat extraction.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.